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pH regulationThe mammalian Na+/H+ exchanger isoform 1 (NHE1) is a ubiquitously expressed integral membrane protein
present in mammalian cells. It is made up of a hydrophobic 500 amino acid membrane domain that transports
and removes protons from within cells, and a regulatory intracellular cytosolic domain made of approximately
315 amino acids. Determining the structure of NHE1 is critical for both an understanding of the Na+/H+
exchange mechanism of transport, and in the design of new improved inhibitors for use in treatment of several
diseases in which it is involved. Differing models of the NHE1 protein have been proposed. The ﬁrst model
suggested by two groups proposes that amino acids 1–500 form a 12 transmembrane segment spanning region
in which amino acids 1–127 form two transmembrane segments, and amino acids 315–411 form a single
transmembrane segment with membrane associated segments. A second model based on the structure of the
Escherichia coli Na+/H+ exchanger protein proposes an overall similar topology, but suggests amino acids 1–
127 are removed as a signal sequence and are not present in the mature protein. It also suggests a different
topology of amino acids 315–411 to form three transmembrane segments. We used cysteine scanning
accessibility and examination of glycosylation of themature protein to characterize theNHE1 protein. Our results
demonstrate that themodel of NHE1 is correct which suggests that amino acids 1–127 form two transmembrane
segments that remain connected to the mature protein, and the segment between amino acids 315–411 is one
transmembrane segment.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The Na+/H+ exchanger (NHE) is a membrane transport protein
ubiquitously present in living organisms. Inmammals, its primary func-
tion is to protect cells fromexcess intracellular acid,which it achieves by
catalyzing the electroneutral removal of a single intracellular H+ in ex-
change for one extracellular Na+. The ubiquitous isoform one (NHE1),
was the ﬁrst isoform discovered in 1989 [1,2]. Ten isoforms of NHE are
currently known to exist (NHE1–10) with different tissue expression,
cellular localization and physiological roles. Some types are mainly
present on intracellular organelles (NHE6–9) while others NHE1–5,
are mainly plasma membrane proteins. NHE1 is made up of 815
amino acid residues separated into two domains— anN-terminal trans-
membrane (TM) domain where ion transport is catalyzed and a C-
terminal cytosolic domain that regulates the ion transport activity [3].
Themajor physiological role of NHE1 is regulation of intracellular pH
but it is also involved in cell differentiation, cell proliferation, cell
volume regulation, cytoskeletal organization and cell migration. Inyl)-5(6) carboxyﬂuorescein-
agglutinin; NHE1, Na+/H+ ex-
pe.transformed cells, alkalinizationmediated byNHE1 plays also an impor-
tant role in the development of the transformed phenotype and this is
prevented when NHE1 is inhibited [4,5]. NHE1 also plays a clear role
inmammaliandevelopment.Micewith aNHE1deletion have decreased
postnatal growth and increased mortality, ataxia and epileptic seizures
[6] and we have recently demonstrated that homozygous expression
of a defective NHE1 gene in humans results in disease,with a phenotype
including hearing loss and cerebellar ataxia [7].
The structure of the Escherichia coliNa+/H+ exchanger NhaA [8] and
that of NapA from Thermus thermophilus has been elucidated [9]. Brieﬂy,
the crystal structure of NhaA [8] contained two groups of 6 transmem-
brane (TM) segments each had two three TM bundles. TMIV and
TMX1make a novel foldwith extended non-helical regions that crossed
andwere thought to contain various charged residues important for ion
binding and transport. That protein was in an acid locked state and not
active however the structure of NapAwas determined in an active state
with signiﬁcant differences from NhaA. A two domain, rocking bundle,
alternating access model of sodium proton antiport was hypothesized
[9] though elements of this model have been disputed [10]. The struc-
ture of another Na+/H+ exchanger, the archaeal Na+/H+ antiporter
NhaP1, has been determined at 7Å resolution and it varies from NhaA
with 13 membrane spanning TM segments instead of 12, but the 6
helix bundle structure is conserved and similar to that of NhaA [11].
While signiﬁcant progress has beenmade describing the prokaryotic
Na+/H+ exchanger NhaA structure and on some other primitive types,
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mammalian isoforms of the protein. Mammalian Na+/H+ exchangers
have little homology to NhaA and a 1:1 stoichiometry, in contrast toFig. 1.the 2:1 stoichiometry of NhaA. The NHE1 isoform is the only mammali-
an type with signiﬁcant progress made in direct examination of its
structure.While the entire protein is resistant to large scale overexpres-
sion and crystallization, we have been able to examine the structure of
TM segments by NMR [12–18]. These studies have revealed interesting
characteristics of the TM segments that are similar to some segments of
NhaA. However, they cannot give a complete picture of the structure of
the protein without a better understanding of the overall topology of
the protein.
Wakabayashi et al. [19] used cysteine scanning accessibility experi-
ments to make an initial analysis of the topology of NHE1. They sug-
gested a 12 TM model based on the accessibility of the residues tested
with the N- and C-terminus in the cytoplasm. They proposed two intra-
cellular loops, between TMs IV–V (amino acids 176–190) and VIII–XI
(316–338), which contained amino acids that were accessible extracel-
lularly but were suggested to be intracellular and part of re-entrant
loops (Fig. 1A, B). Amino acids 341–362 formed TM segment IX, and ex-
tracellular loop 5 that was thought to be associatedwith themembrane.
An alternate 3D model of NHE1 was later proposed based on the struc-
ture of NhaA as a template [20]. Thismodel also contained 12 TMhelices
but had several notable differences. It did not include the ﬁrst two heli-
ces of the model of the Wakabayashi model (1–125), which were
thought to be removed by cleavage (Fig. 1A). TMIX (339–359) was
assigned as two short helices and a re-entrant segment between
TMIX-X is reassigned as TMIX (374–398) (Fig. 1C). This rearrangement
of the re-entrant loop placed EL5 (360–410), which had numerous ex-
tracellularly accessible residues [19], on the inside of the membrane.
They suggested that this loop could be near the pore of the protein, ac-
counting for this accessibility. The last three TMs (411–505) are the
same in bothmodels (Fig. 1).More recently Nygaard et al. [21] proposed
amodel of NHE1 that was based on the NhaAmodel and on thework of
Wakabayashi et al. [19]. The model of Nygaard et al. [21] has also
proposed a 12 transmembrane structure of NHE1. The overall two
dimensional conﬁguration of this model is similar to that of the
Wakabayashi model with the main differences in the membrane seg-
ments being the beginning and end of some of the helices. Most of the
beginnings and ends of the transmembrane segments were very similar
(TM's I–VIII, and X–XII), varying by 2–5 amino acids while TMIX was
amino acids 339–359 and 333–353 in these two models, respectively
[19,21] (the models were recently reviewed by [22]). Nygaard et al.
attempted to verify one part of theirmodel using electron paramagnetic
resonance, but theirﬁnalmodel suggested that the charged side chain of
D172 is critical to NHE1 function and it has been shown thatmutation of
this residue to N or Q did not impair NHE1 function [23]. Clearly a great-
er reﬁnement of existing models of NHE1 is necessary and more direct
characterization of the structure of NHE1 is necessary. The controversy
in the area has continued [24,25].
In the present study, we examined the accessibility of numerous
amino acid residues of themature NHE1 protein, to distinguish between
these threemodels.We studied the regions that are more controversial,
the N-terminal amino acids 1–127 and the segment containing amino
acids 315–411. Further, we used immunoprecipitation of the mature
surface protein and an analysis of the N-linked glycosylation of the pro-
tein to study the N-terminal transmembrane segments. The results are
consistent with amino acid residues 1–127 forming two transmem-
brane segments that remain connected to the mature protein, and the
segment between amino acid residues 315–411 forming one trans-
membrane segment as proposed by Wakabayashi et al.'s [19] model.Fig. 1.Models of topology of the NHE1 protein. A, Schematic diagram of transmembrane
domain of NHE1 protein. Transmembrane segments 1–12 are illustrated together as sug-
gested by Wakabayashi et al. [19,21] (model #1). Shaded areas are regions in dispute in
model #2 [20]. Transmembrane segments 1–2 were suggested to be deleted in model
#2. An alternate topology of amino acid residues 315–411 is illustrated above frommodel
#2. B and C show detailed alternative topologies of amino acid residues 315–411 models
#1 and #2, respectively. EL, extracellular loop; IL, intracellular loop. * indicates amino acid
mutated to Cys in the present study.
Table 1
Oligonucleotides used for site-directed mutagenesis of cNHE1. Mutated nucleotides are
lower case, restriction sites created are bold, (–) denotes site removed.
A
Mutation Oligonucleotide sequence Site
S8C GGTCTGGCATCTgcGGcttaagTCCACATCGGATC AﬂII
S44C GCCCAACTGCCtGtACaATTCGAAGCTCAG BsrGI
T97C GGCATCGACTACtgtCACGTcCGgACCCCCTTC BspEI
T101C CACACGTGCGCtgCCCCTTCGAaATCTCCCTCTG –BglII
F318C CGGGGTCATCGCAGCaTgCACCTCCCGATTTAC SphI
S320C CGCAGCCTTCACCTgCaGATTTACCTCCCAC PstI
I326C CGATTTACCTCCCACtgCaGGGTCATCGAGCCG PstI
E330C CACATCCGGGTCATatgcCCGCTCTTCGTC NdeI
S338C GTCTTCCTCTACtGCTACATGGCCTACTTGT
CtGCaGAGCTCTTCCAC
PstI
S344C GCCTACTTGTgtGCCGAaCTCTTCCACCTG –SacI
A345C GCCTACTTGTCAtgCGAaCTCTTCCACCTG –SacI
Y366C GATGCGCCCCTgtGTGGAGGCCAAtATtTCCCACAAGTC SspI
A369C CTATGTGGAGtgCAAtATtTCCCACAAGTC SspI
I371C GTGGAGGCCAACtgCagCCACAAGTCCCAC PstI
T377C CACAAGTCCCACtgtACaATCAAATACTTC BsrGI
L383C CACCATCAAATAtTTCtgtAAGATGTGGAGC SspI
S401C CTTCCTCGGCGTCtgtACaGTGGCCGGCTC BsrGI
T402C GGCGTCTCCtgcGTGGCCGGaTCCCACCAC BamHI
S406C CCTCGGCGTCagtACtGTGGCCGGCtgCCACCACTGG ScaI
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2.1. Materials
2′,7'-Bis(2-carboxyethyl)-5(6) carboxyﬂuorescein acetoxymethyl
ester (BCECF-AM) was from Molecular Probes, Inc. (Eugene, OR).
Streptavidin agarose and streptolysin O were purchased from Sigma,
(St. Louis, MO, USA), Sulfo-NHS-SS-biotin was obtained from Pierce
Chemical Company (Rockford IL, USA) and synthetic DNA was pur-
chased from IDT (Coraiveille, IA, USA). Immobilized streptavidin was
from Sigma-Aldrich (St Louis MO, USA). Geneticin antibiotic was from
American Bioanalytical (Natick MA, USA). O-Glycosidase and PNGaseF
were from New England Biolabs Inc. Cell culture MEM alpha modiﬁca-
tion medium was purchased from Thermo Fisher Scientiﬁc Hyclone
(Logan UT, USA). pH measurements used 2′,7′-bis (2-carboxyethyl)-
5(6) carboxyﬂuorescein-acetoxymethyl ester purchased from Molecu-
lar probes, Inc. (Eugene OR, USA). PWO DNA polymerase was from
Roche Applied Science (Roche Molecular Biochemicals, Mannheim,
Germany). For transfection, Lipofectamine 2000 reagent was from
Invitrogen Life Technologies (Carlsbad CA, USA). Other chemicals that
were used were of analytical grade and were from Fisher Scientiﬁc
(Ottawa, ON, Canada), Sigma (St. Louis, MO, USA) or BDH (Toronto,
ON, Canada). The plasmid pYN4+ has been described earlier [26] and
contains the human NHE1 protein with a C-terminal HA (hemaggluti-
nin) tag. We have earlier shown the cysteineless NHE1 (cNHE1) is
fully functional [7].
2.2. Site-directed mutagenesis
Site-directed mutagenesis was on cNHE1 as described earlier [18].
Mutations were designed to create or delete a restriction enzyme site.
DNA sequencing conﬁrmed the ﬁdelity of DNA ampliﬁcation andmuta-
tions. Table 1 summarizes the mutations made.
2.3. Cell culture and stable transfection
To characterize the activity of the Na+/H+ exchanger we used mu-
tant Chinese hamster ovarian cells that do not express endogenous
NHE1 (AP-1 cells) [1]. Stably transfected cells were made using
LIPOFECTAMINE 2000 Reagent (Invitrogen Life Technologies, Carlsbad,
CA, USA) as described earlier [18]. The NHE1 expression plasmid
(pYN4+), contains a neomycin resistance gene for selection of stably
transfected cells using geneticin (G418). Stable cell lines for experi-
mentswere regularly re-established from frozen stocks at passage num-
bers between 5–11. Results are typical of at least two stable cell lines of
each type of mutant.
2.4. Cell surface expression
Targeting of the NHE1 protein to the cell surface was measured as
described earlier using sulfo-NHS-SS-biotin labeling [27]. Brieﬂy, the
cell surface was labeledwith sulfo-NHS-SS-biotin and cells were solubi-
lized. The cell surface NHE1 protein was removed from solubilized pro-
teins with immobilized streptavidin resin. We used SDS-PAGE and
western blotting to examine equal amounts of unbound and total pro-
tein using anti-HA (NHE1-tag) antibodies. The image densities on the
western blots were estimated using Image J 1.35 software (National In-
stitutes of Health, Bethesda, MD, USA). It was not possible to efﬁciently
and reproducibly elute proteins bound to immobilized streptavidin
resin. The amount of NHE1 on the plasma membrane was estimated
by comparing both the upper and lower HA-immunoreactive species.
2.5. Accessibility of residues
The accessibility of residues of NHE1 was determined based on pro-
cedures we have used earlier [13]. Stable cell lines with mutations inNHE1were grown to conﬂuence andwashedwith phosphate buffer sa-
line (PBS). They were then treated +/−10 mMMTSET for 20min at 37
°C in a buffer consisting of 135 mM NaCl, 5 mM KCl, 1.8 mM CaCl2,
1.0mMMgSO4, 5.5mMglucose and 10mMHEPES, pH 7.3 (normal buff-
er). Cells were washed three times with PBS and then 2 ml of a lysis
buffer was added, consisting of 25 mM Tris HCl, pH 7.4, 150 mM NaCl,
1 mMEDTA, 1% NP-40, 5% glycerol and 37.5 μMALLN and a protease in-
hibitor cocktail [28]. Cells were scraped off and sonicated two times for
15 s. The solution was spun at 35,000 rpm (100,000 ×g) for 1 h and the
supernatant was collected. HA-tagged NHE1 protein was immuno-
precipitated from the supernatant. For immunoprecipitation we used
the Pierce Crosslink IP kit in which the primary antibody was
crosslinked to Protein A/G agarose beads. This enabled immunoprecip-
itation without contamination from the primary antibody. The primary
antibody used for immunoprecipitation was a commercially obtained
rabbit polyclonal against the HA tag (Santa Cruz, sc-805). After immu-
noprecipitation, the sample was divided into two. One sample was
used to quantify the total NHE1 protein via western blotting. To the sec-
ond sample IRDye800-maleimide (LI-COR) was added (ﬁnal concentra-
tion 0.2 mM) which would react with any unblocked sulfhydryls of the
introduced cysteine. Samples were separated by SDS-PAGE and we ex-
amined the protein, which reacted with the IRDye800-maleimide
using a LI-COR system. Calculations were, MTSET accessibility =
100− %(Fluorescence in the presenceMTSET / Fluorescence in absence
of MTSET). Readings were corrected for the amount of NHE1whichwas
immunoprecipitated by Western blotting for NHE1 with a monoclonal
antibody against the HA tag.
In some experiments, cells were permeabilized with streptolysin O
prior to determination of accessibility of intracellular loops. Mutant
cell lines (S8C, F318C, S320C, I326C, S338C, A345C) were prepared as
described above. Brieﬂy, cells were washed with PBSCM (PBS plus
0.1 mM CaCl2 and 1 mM MgCl2) two times, followed by washing the
cells with cold incubation buffer (25mMHepes; 115mMpotassium ac-
etate; 2.5mMMgCl2; 1mMdithiothreitol; pH 7.4). Cellswere incubated
with (or without) 350 units/ml SLO in 2 ml of incubation buffer for
15 min on ice. Cells were washed with warm incubation buffer
(37° C30 min) and then with PBSCM. They were treated +/−MTSET
(10 mM) in normal buffer for 20 min at 37°C. Then washed 3times
with PBS. Cells were then harvested and examined for NHE1 accessibil-
ity as above.
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Expression of NHE1 was conﬁrmed by immunoblotting using anti-
bodies against the HA tag on the NHE1 C-terminus. Samples were run
on 10% SDS-PAGE gels and were electrotransferred to nitrocellulose
membranes for incubation with anti-HAmonoclonal antibody. The sec-
ondary antibody used for signal detection was peroxidase-conjugated
goat anti-mouse antibody (Bio/Can,Mississauga, Canada). Reactive pro-
tein was detected on X-ray ﬁlm using the Amersham enhanced chemi-
luminescence western blotting and detection system.
2.7. Intracellular pH measurement
BCECFwas used tomeasureNHE1 activity and to quantify intracellu-
lar pH (pHi) recovery after an acute acid load as described earlier [18].
Cells were grown to≈90% conﬂuence on coverslips and ﬂuorescence
was measured using a PTI Deltascan spectroﬂuorometer with the pa-
rameters described earlier. Brieﬂy, acute acidosis was induced by am-
monium chloride prepulse, 50 mM × 3 min addition followed by
withdrawal. The ﬁrst 20 s of recovery from acidiﬁcation and was mea-
sured as ΔpH/s. Calibration of intracellular pH ﬂuorescence was done
for each sample as described earlier [18]. Results are shown as the
mean±S.E. of at least 6 experiments and statistical signiﬁcancewas de-
termined using theWilcoxon Signed-Rank test. Variations in the level of
surface targeting and protein expression were used to correct for activ-
ity of the protein as described earlier [15,29].
2.8. Characterization of glycosylation
A series of experimentswere carried out to characterizeNHE1 glyco-
sylation and to determine if NHE1 protein was glycosylated at N75 of
the ﬁrst extracellular loop, and if NHE1 containing glycosylation at
N75 was present at the cell surface. AP1 cells were transiently
transfected with wild type HA-tagged NHE1 cDNA [7]. Proteins present
at the cell surface were labeled with sulfo-NHS-SS-biotin as described
earlier [18] and immobilized streptavidin resin was used to remove
cell surface labeled protein. Brieﬂy, cells were grown to conﬂuence in
100 mm plates and were rinsed sequentially with 4 °C PBS and borate
buffer [154 mM NaCl, 7.2 mM KCl, 1.8 mM CaCl2, and 10 mM boric
acid (pH 9.0)]. The cells were then incubated for 30min at 4 °C in borate
buffer, containing sulfo-NHS-SS-biotin (0.5 mg/ml). Cells were washed
with quenching buffer [192 mM glycine and 25 mM Tris (pH 8.3)] and
then harvested with 500 μl of ice cold IPB [1% (v/v) IGEPAL CA-630,
0.5% (w/v) deoxycholic acid, 150 mM NaCl, 5 mM EDTA, and 10 mM
Tris–HCl (pH 7.5)], containing complete protease inhibitor and solubi-
lized for 20 min on ice. Tubes containing cell lysates were centrifuged
for 20 min at 13,000 g and 4 °C. The supernatant was collected in a
fresh tube. Depending on the experiment, the supernatant was divided
into two equal parts and both sets were incubated separately with 50 μl
of streptavidin agarose resin for 16 h at 4 °Cwith gentle rotation. The su-
pernatant was collected after centrifugation for 2 min at 8000 g. The
resin from one of the two sets, which now has bound biotinylated pro-
teins, was treatedwith 500U of PNGase F (NEB) [1 μl from stock], 1×G7
(provided with PNGase F) reaction buffer and 1% NP-40 at 37 °C for 4 h.
Resin in the other tube was treated similarly with only 1× G7 reaction
buffer and 1% NP-40. Tubes were vortexed every 10–15 min for proper
enzyme action. After 4 h resin from both tubes were treated with SDS-
PAGE sample buffer at 65 °C for 10min. Samples were run on 10% acryl-
amide SDS-PAGE gel and transferred to PVDFmembrane. Immunoblot-
ting was with anti-HA monoclonal antibody as described earlier [27].
Another series of experiments used NHE1-HA cDNA that had N75
mutated to D as described earlier, whichwould prevent N-linked glyco-
sylation [30]. Cells were transiently transfected with one of the two
NHE1 cDNA's and then the size of the NHE1 protein was examined by
immunoblotting in either whole cell lysates or in intact cells.3. Results
3.1. Alternative topologies
Fig. 1 outlines the alternative topologies of the NHE1 protein.
Model #1 is based on the topologies of Wakabayashi et al. and
Nygaard et al. [19,21]. Given the minor differences in the ends of
the transmembrane segments of these two models [22], one repre-
sentative two-dimensional model was used referred two as model
1. Here amino acid residues 1–127 remain as an integral part of the
intact full-length protein and amino acid residues 315–411 have
two membrane associated regions and one transmembrane seg-
ment. In model #2, the ﬁrst two transmembrane segments were pro-
posed to be cleaved and removed as a signal sequence [20] while an
alternative topology was proposed for amino acid residues 315–411
(Fig. 1B, C). To test these differing hypotheses we made a series of
mutants of the cysteineless NHE1 protein inserting single cysteine
residues in the two areas of contention (Table 1). Nineteen muta-
tions were successfully made in the cNHE1 protein and stable cell
lines were successfully made expressing each of these mutant copies
of NHE1. The mutations were in the proposed intracellular N-
terminus (S8C), in the ﬁrst extracellular loop (S44C, T97C, T101C)
and a series of ﬁfteen mutations in a contentious region from resi-
dues 315–411 (Fig. 1B,C). Five other mutations were attempted
(I128C, V334C, M340C, M363C and T378C) but for reasons that are
presently unclear, we were not able to obtain either successful muta-
tions or stable cell lines expressing these mutations.
3.2. Characterization of mutants
Initially we characterized the expression, activity and cell surface
targeting of allmutants to ensure that an active and properly folded pro-
tein was obtained. The results are shown in Fig. 2. A comparison of the
levels of expression of the various mutant proteins is shown in Fig. 2A.
Most of themutants expressed NHE1 at levels similar to that of the con-
trol, +/−20%. A few, A345C, T377C, L383C and S406C were up to 50%
lower in expression levels but still had easily identiﬁable and quantiﬁ-
able protein.
Fig. 2B shows that most of themutants had levels of surface process-
ing similar to that of the control, cysteineless NHE1. The Y366C and
I371C mutants were up to 12% lower in targeting compared to control,
though still had appreciable levels of protein targeted to the cell surface.
We then compared the activity of the mutants to that of the cNHE1
protein (Fig. 2C). Most of the mutant proteins retained over or near
40% of the value of the control. A few, T101C, E330C, A345C, and
L383Cwere less than 25% of the control level. The E330C and L383Cmu-
tant proteins were under 16% of the control level activity, and were ex-
cluded from further experiments on accessibility. When correcting for
the amount of protein and the surface targeting it was apparent that
the same mutants, T101C, E330C, A345C, and L383C had defective pro-
tein activity that was due to an effect on the protein itself and not due to
defective targeting or expression levels.
3.3. Accessibility studies
To gain novel insights into the topology of the NHE1 protein and to
compare and contrast the two existing models of the protein we exam-
ined the surface accessibility of the mutant amino acid residues that
were present in functional NHE1 proteins. The results are shown in
Fig. 3. Fig. 3A shows one typical result and Fig. 3B a summary of 3–5 ex-
periments. NHE1 mutant proteins with cysteine residues at amino acid
residue positions, S8, S44, F318, S320, I326, S338, S344, A345, I371 and
S406were not accessible toMTSET blockage of reactionwith IRDye800-
maleimide. NHE1mutant proteins with cysteine residues at amino acid
positions T97, T101, Y366, A369, T377, S401 and T402 were suscepti-
ble to MTSET blockage of reaction with IRDye800-maleimide. As the
Fig. 2.Characterization of Na+/H+ exchangermutants expression, targeting and activity. A,Western blot of cell lysates of stable cell lines expressing full lengthNa+/H+ exchangermutants
or control NHE1 protein using anti HA-antibody. Mutations are indicated. Equal amounts of cell lysate were loaded in each lane. Numbers below each lane indicate the amount of Na+/H+
exchanger protein relative towild typeNa+/H+ exchanger.Mean values (nN 3–4)were obtained fromboth the 110 and 95-kDabands. AP-1 refers toAP-1 cells not transfectedwithNHE1.
Wt, refers to cells stably expressing wild type cysteineless NHE1 protein. B, Surface localization of NHE1 in AP-1 cells expressing control or NHE1 mutant proteins. Equal amounts of total
cell lysate (left lane) and unbound intracellular lysate (right lane) were examined using Western blotting with anti-HA antibody to identify the NHE1 protein. cNHE1 is from a cell line
stably expressing cysteineless NHE1 protein. The percent of the total NHE1 protein found on the cell plasma membrane is indicated for each mutant. Results are the mean ± the S.E.
n= at least 3 determinations. C, Summary of the rate of recovery after an acute acid load of AP-1 cells transfectedwithwild typeNHE1 andNa+/H+ exchangermutants. Themean control
activity of cells stably transfected with NHE1 was .014 Δ pH/s, and this value was set to 100%. Other activities are a percent of those of cNHE. Values are the mean ± SE of 6–10
determinations. Results are shown for mean activity of both uncorrected (black) and normalized for surface processing and expression levels (cross hatch).
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Fig. 3. The accessibility of cysteine residues of NHE1mutants to reactivity withMTSETwas
measured as described in the “Materials and methods”. A, Illustrates examples of MTSET
blocking of reactivity with IRDye800-maleimide. Prior reaction with MTSET blocks the
reactivity with IRDye800-maleimide when the residue is accessible. + indicates reacted
with MTSET prior to reaction with IRDye800-maleimide. B, Summary of the accessibility
of various NHE1 mutant proteins. Results are the mean ± SE of at 3–5 experiments. C,
Effect of cell permeabilization on accessibility of putative intracellular amino acids of
NHE1. Cells (S8C, F318C, S320C, I326C, S338C, A345C) were treated with or without
streptolysin O as described in the Materials and methods. They were then tested for
accessibility as described above + indicates reacted with MTSET prior to reaction with
IRDye800-maleimide. Results are typical of at least 3 experiments.
2390 Y. Liu et al. / Biochimica et Biophysica Acta 1848 (2015) 2385–2393experiment was done in intact live cells and MTSET is impermeable to
the plasma membrane, this indicated that these residues were accessi-
ble to the extracellular surface.
To conﬁrm that residues S8, F318, S320, I326, S338 and A345 of the
NHE1 protein were intracellularly located we permeabilized cells with
streptolysin O and examined the accessibility of these residues to
MTSET (Fig. 3C). Treatment with streptolysin O, allowed MTSET block-
age of the reaction with IRDye800-maleimide. This suggested that
these residues were accessible on the intracellular surface.
3.4. Study of N-linked carbohydrates and extracellular loop 1
Cysteine scanning accessibility experiments of the ﬁrst extracellular
loop suggest that the protein that is present on the extracellular surface
contains this segment. However, an argument could be made that this
represents a subfraction, perhaps aminority, of the entire NHE1 protein.
To counter this argument, we did experiments in which we examined
the status of cell surface NHE1 protein. We determined if NHE1 at the
cell surface contained glycosylatedNHE1 protein by labeling cell surface
proteins with sulfo-NHS-SS-biotin. Immobilized streptavidin was used
to pull down labeled surface proteins. Cell surface proteinswere treated
with PNGaseF, which catalyzes removal of N-linked oligosaccharides
from glycoproteins. The results are shown in Fig. 4A. Treatment with
PNGaseF caused an increase in mobility of the NHE1 protein conﬁrming
that NHE1 on the cell surface contains N-linked oligosaccharides.
Based on current topology models of NHE1 [19,20], the consensus
sequence of N-linked glycosylation, and a previous report [31], N75 is
the only site for N-linked carbohydrate addition. We conﬁrmed that
N75 of the ﬁrst extracellular loop, is used for glycosylation. AP1 cells
were transfected with either wild type NHE1 protein or with NHE1 pro-
tein that had an N75 to D mutation. Western blot analysis of total pro-
teins of cell lysates showed that the NHE1 protein with a N75D
mutation was of reduced molecular size compared to the wild type
Fig. 4B.
We also examined if the N75D containingNHE1 proteinwas present
at the cell surface (Fig. 4C). Cell surface proteins were labeled with
sulfo-NHS-SS-biotin and immobilized streptavidin was used to pull
down labeled proteins. Both wild type and N75D proteins were present
on the cell surface and the apparentmolecular weight of the N75D pro-
tein was again reduced, in comparison to the wild type NHE1 protein.
4. Discussion
4.1. NHE1 physiological signiﬁcance
The topology of the NHE1 protein is of great interest both from a
purely scientiﬁc point of view and from an applied standpoint. Scientif-
ically, the mechanism of Na+/H+ exchange is of great interest to a wide
audience.While signiﬁcant progress has beenmade in the structure and
function of prokaryotic Na+/H+ exchangers [8] much less has been
made in the analysis of mammalian NHE's which has little homology
to bacterial Na+/H+ antiporters and a different stoichiometry (reviewed
in [3]). Na+/H+ exchange represents a fundamental and critical cellu-
lar process being important in cell growth, human development and
differentiation [32]. It thus is of great fundamental interest to
science.
Aside from a fundamental science point of view, mammalian
NHE1 is an important putative target in several diseases. It is impor-
tant in ischemic heart disease, heart hypertrophy and plays a critical
facilitative role in some types of cancer [5,33–35]. NHE1 inhibitors
have been developed to provide cardioprotection from heart disease
unfortunately these have not been very successful, possibly due to
poor administration protocols that lead to non speciﬁc effects of
the inhibitor [36]. While a myriad of NHE1 inhibitors has been devel-
oped [37], a fundamental knowledge about their speciﬁc site of in-
teraction with the protein is unclear [38] and though TMVI of NHE1
Fig. 4. Characterization of N-linked glycosylation site of NHE1. A, Cells were transfected
with HA-tagged NHE1 containing plasmid and cell surface proteins were labeled by bio-
tinylation. Surface accessible proteins were precipitated with immobilized streptavidin
and then treated with PNGAseF as described in the “Materials and methods”. Western
blot analysis was with anti-HA antibody. B, Cells were transfected with HA-tagged NHE1
protein or with NHE1 protein with the N75D mutation. Whole cell lysates were probed
by Western blot analysis as described in “A”. C, Cells were transfected with HA-tagged
Wt NHE1 containing plasmid or plasmid with the N75D mutation. Cell surface proteins
were obtained as described in “A”. Western blot analysis was with anti-HA antibody.
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[39], clearly a greater understanding of the basic structure of NHE1
is desirable, to lead to the design of new and improved inhibitors.4.2. Evidence towards alternative topology models
As noted above, two fundamentally different types ofmodel of NHE1
have been put forth. One was by the group of Wakabayashi [19] which
used cysteine scanning accessibility experiments and was later reﬁned
by Nygaard et al. [21] (model #1). A second and different model
(model #2) was by the group of Landau et al. which modeled NHE1
after the structure of NhaA [20]. The fundamental differences between
these two models are illustrated in Fig. 1. Brieﬂy, the model of Landau
et al. suggested that transmembrane segments encompassing the ﬁrst
125 amino acid residues were deleted from the full-length protein
(Fig. 1A) and also proposed a different topology for amino acid residues
315–411 (Fig. 1B,C). The predicted topology of residues 126–314 and
residues 412–500 is quite similar in the model of Landau, Nygaard and
Wakabayashi as recently reviewed [22].
Our experiments with cell surface accessibility were on two regions
of the protein. The proposedﬁrst two transmembrane segments are res-
idues 1–125 and the region from residue 315 to residue 411. Model #2
[20] suggested that these two transmembrane segments could be
cleaved and removed in the mature NHE1 protein. This is in contrast
with model #1. Wakabayashi [19] also directly demonstrated that sev-
eral amino acids on extracellular loop 1 were extracellular according
to cysteine accessibility studies. Our results support the inclusion of
the ﬁrst two transmembrane segments as part of the whole intact
NHE1 protein in the topology proposed by model #1 by Wakabayashi
et al. [19] andNygaard et al. [21]. Firstly,we found that proteins contain-
ing amino acid residues that we mutated in this region were fully
expressed similar to thewild typeNHE1protein in both size and expres-
sion levels. The apparent molecular mass of the NHE1 protein was ap-
proximately 100 kDa, which is not consistent with removal of these
two transmembrane segments. Additionally, the introduction of cyste-
ine residues in this region produced proteins that were accessible to ex-
tracellular labeling. For example T97 and T101 were both accessible to
extracellularMTSET, which indicated that these amino acids were pres-
ent in the full-length intact protein. Further, this conﬁrms an extracellu-
lar localization for extracellular loop 1which is comprised of amino acid
residues 35 to 104. Our results with amino acid residues T97 and T101
conﬁrm that thismore proximal region is also accessible from the extra-
cellular surface. Amino acid residue S44wasnot readily accessible in our
experiments in contrast to the earlier report [19]. The reason for this is
not clear but this does not detract from the preponderance of evidence
which shows that this region of the protein is extracellular, and a part of
the intact full length NHE1 protein.
The amino acid residue at position number 8 was returned to its na-
tive Cys from a Ser residue in the cNHE1 protein. It was not accessible to
extracellular MTSET. However, when cells were permeabilized with
streptolysin O, this amino acid became accessible. This conﬁrmed that
this short N-terminal extension of NHE1 was present in the full length
protein and supports and intracellular localization, consistent with the
model #1 [19].
The above data suggest that amino acid residues 1–101 are present
in the full-length protein. However, an argument could be made that
this was only a fraction of the NHE1 protein that we examined and
that the ﬁrst two segments are removed frommost of the NHE1 protein
that is present on the cell surface.While this seems unlikely, we provid-
ed evidence against it and further evidence that amino acids 40–105
form an extracellular loop present in the intact full-length protein.
Counillon et al. [40] showed that only consensus site for N-linked glyco-
sylation of NHE1 is on N75. Our experiments were to demonstrate that
this site on the protein was present at the cell surface. To do this, we
used protein with or without this site that had been recovered from
the cell surface by cell surface labeling the proteins with biotin and re-
covering them with streptavidin. Thus any NHE1 protein could not
have been from within the cell. We found that protein containing the
N75 site was present on the cell surface. Mutation of amino acid N75
showed that the glycosylation was at this location even though both
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cell surface (Fig. 4B,C). These results conﬁrm that the NHE1 protein on
the cell surface contained the N75 site. We also found that the enzyme
PNGaseF reduced themolecular weight of the NHE1 that was recovered
from the cell surface as described above. This further conﬁrmed that the
extracellularNHE1was glycosylated (Fig. 4A). Of note also, the apparent
molecularweight of the protein from the cell surface thatwas either de-
glycosylated enzymatically, or had the N75D mutation, was approxi-
mately 100 kDa. Removal of the ﬁrst two transmembrane segments
would result in a protein of approximately 81.5 kDa with the HA tag.
This also suggests that the ﬁrst 127 amino acid residues remain on the
plasma membrane NHE1 protein. Taken together, the experiments
demonstrate that the N75 site is present on the mature NHE1 protein
on the cell surface, conﬁrming that this region is present in the mature
protein.
The next set of experiments was to examine the transmembrane
segment containing amino acid residues 315–411. Thirteen mutations
were made in this general region. Fig. 5 shows schematic diagrams of
the two alternate models of amino acid residues 315–411. Results of
our experiments are shown with solid colors, red indicating a residue
inaccessible from the extracellular surface, and green indicating a resi-
due accessible from the extracellular surface. Results from the study of
Wakabayashi et al. [19] are also indicated with cross hatches using the
same color scheme. We made six mutations between amino acids 315
and 345. All of thesewere not accessible from the exterior of the cell in-
cluding amino acid position 326 (Figs. 5, 3B). The results with residues
318 and 320 are consistent with either model (Fig. 5). Results with res-
idues 326 are also consistent with either model. Though it was previ-
ously demonstrated that residues 324 and 325 are accessible from the
outside (Fig. 5) it was hypothesized [19] that this was due to an
infolding of this intracellular loop. When cells were permeabilized
with streptolysin O, residues at position 318, 320, 326, and 338 became
accessible. This further supports an intracellular location for these resi-
dues. Streptolysin O has been used earlier to permeabilize cells and de-
termine if particular amino acids of transmembrane proteins have an
intracellular location. However, it would not result in accessibility with-
in the plane of the membrane, which allows an assignment to intracel-
lular loops between transmembrane domains [19,41].
Amino acid residues 344 and 345 were not accessible from outside
the cell. This was more consistent with model 1 and inconsistent withFig. 5. Alternate topologymodels of amino acid residues 315–411 of the NHE1 protein. Left pan
ﬁlled residue indicates results from the present study indicating residues accessible to MTSET
accessibility). Red ﬁlled residue indicates results from the present study indicating residues
(indicating lack of accessibility). Results from Wakabayashi et al. [19] are also illustrated for co
lack of extracellular accessibility. *Indicates the residue became accessible after cells were permthe model #2 [20] which placed them on an extracellular side of the
membrane. Permeabilization of the cells with streptolysin O rendered
residue 345 accessible, further supporting an intracellular location,
and again supporting model #1.
The segment fromamino acid residue 363 to residue 381 is proposed
to be an extracellular loop in model #1 but is proposed to be intracellu-
lar in model #2 [20]. We made 4 mutant proteins in this region that we
characterized. Three of these (with mutations at 306, 369 and 377)
were readily accessible from the extracellular surface. Amino acid resi-
due at position 371 was not. Previous experiments showed that 8
other amino acid residues within this segment (Fig. 5) are also accessi-
ble from the extracellular face. Overall, this gives a very strong prepon-
derance of evidence favoring this segment as an extracellular loop and
not being intracellular or embedded within the membrane. Though
one amino acid residue (371) was inaccessible from outside the cell,
this can easily be explained as being due to folding of the extracellular
loopwhichmight prevent extracellular chemical association, something
we have seen earlier [16].
Accessibility studies of amino acid residues 401–411 also place this
region on the outside of the cell. Our studies placed residues 401 and
402 outside the cell, which agrees with earlier studies that conﬁrmed
that amino acids 407–409 are outside the cell. While we did ﬁnd that
amino acid position 406 was not accessible, the large preponderance
of evidence is that this region is extracellular, which is in agreement
with both models.
4.3. Conclusion
Overall, our study on the region from amino acid residue 315 to
residue 411 supports model #1 proposed by Wakabayashi [19] and
Nygaard et al. [21] and disagrees with the model proposed by Landau
[20]. The evidence of our own study, summarized, is that residues be-
tween the segment 315 and 345 are not accessible from the exterior
of the cell, and that the residues 363–381 are accessible from the exte-
rior of the cell. These two observations are inconsistent with placing
these two regions on the opposite side of the membrane as proposed
in model #2 [20]. Additionally, our evidence is in agreement with the
cysteine scanning accessibility experiments reported earlier [19] and
with the modeling reported by Nygaard et al. [42] which makes a sum
total of a large number of experiments from three laboratories, thatel, topology afterWakabayashi et al. [19]. Right panel model after Landau et al. [20]. Green
blockage of reactivity with IRDye800-maleimide in intact cells (indicating extracellular
not accessible to MTSET blockage of reactivity with IRDye800-maleimide in intact cells
mparative purposes, green stripes indicate extracellular accessibility, red stripes indicate
eabilized with streptolysin O.
2393Y. Liu et al. / Biochimica et Biophysica Acta 1848 (2015) 2385–2393place residues 315 to residue 345 in an intracellular location and resi-
dues 363–381 outside of the cell.
We suggest thatmodel #1 [19,21] is correct ormuchmore represen-
tative of the true structure of NHE1 for both the presence of the ﬁrst two
transmembrane segments on the protein, and for its proposed topology
of amino acid residues 315–411.
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